Latent Classes of Neuropsychiatric Symptoms in NACC Controls and Conversion to Mild Cognitive Impairment or Dementia
- PMID: 26402012
- PMCID: PMC4635658
- DOI: 10.3233/JAD-150421
Latent Classes of Neuropsychiatric Symptoms in NACC Controls and Conversion to Mild Cognitive Impairment or Dementia
Abstract
Background: A number of studies have linked neuropsychiatric symptoms to increase risk of dementia.
Objective: To determine if risk of conversion to mild cognitive impairment or dementia among healthy controls varied as a function of their pattern of neuropsychiatric symptoms.
Method: We studied individuals in the National Alzheimer Coordinating Center dataset collected from 34 Alzheimer Disease Centers between 2005 and 2013. The analysis included 4,517 volunteers who were ≥60 years old, cognitively normal, and had complete Neuropsychiatric Inventory data at their baseline visit, and had at least one follow-up. We used latent class analysis to identify four classes based on patterns of NPI symptoms. We used a Cox proportional hazards model to determine if time to MCI or dementia varied by baseline latent class membership.
Results: We identified four latent classes of neuropsychiatric symptoms: irritable, depressed, complex (depression, apathy, irritability, and nighttime behaviors) and asymptomatic. 873 participants converted to MCI or dementia. Hazard ratios for conversion by class were 1.76 (95% CI: 1.34, 2.33) for the irritable class, 3.20 (95% CI: 2.24, 4.58) for the complex class, and 1.90 (95% CI: 1.49, 2.43) for the depressed class, with the asymptomatic class as the reference.
Conclusions: Membership in all three symptomatic classes was associated with greater risk of conversion to MCI or dementia; the complex class had the greatest risk. Different patterns of neuropsychiatric symptoms may represent different underlying neuropathological pathways to dementia. Further work imaging and pathology research is necessary to determine if this is the case.
Keywords: Alzheimer’s disease; dementia; depression; latent class analysis; neuropsychiatric symptoms.
Conflict of interest statement
Dr. Leoutsakos has received NIH funding and is an unpaid statistical consultant for Lilly.
Ms. Forrester has no conflicts of interest and no financial relationships to report.
Dr. Lyketsos has received grant support (research or CME) from NIMH, NIA, Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, Glaxo-Smith-Kline, Eisai, Pfizer, Astra-Zeneca, Lilly, Ortho-McNeil, Bristol-Myers, Novartis, National Football League, Elan, and Functional Neuromodulation. He serves as a consultant for Astra-Zeneca, Glaxo-Smith Kline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, NFL Players Association, NFL Benefits Office, Avanir, Zinfandel, BMS, Abvie, Janssen, and Orion. He has received honoraria or travel support from Pfizer, Forest, Glaxo-Smith Kline, and Health Monitor.
Dr. Smith has received NIH funding.
Figures


Similar articles
-
Patterns of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Risk of Dementia.Am J Geriatr Psychiatry. 2016 Feb;24(2):117-25. doi: 10.1016/j.jagp.2015.05.007. Epub 2015 May 16. Am J Geriatr Psychiatry. 2016. PMID: 26209222 Free PMC article.
-
Trajectories of neuropsychiatric symptoms over time in healthy volunteers and risk of MCI and dementia.Int J Geriatr Psychiatry. 2019 Dec;34(12):1865-1873. doi: 10.1002/gps.5203. Epub 2019 Sep 2. Int J Geriatr Psychiatry. 2019. PMID: 31452260 Free PMC article.
-
Empirical Classification of Neuropsychiatric Symptoms and Association of Classes With Diagnostic Progression and Cognitive Decline in Mild Cognitive Impairment and Alzheimer's Disease Populations.Biol Psychiatry. 2025 Jun 1;97(11):1059-1066. doi: 10.1016/j.biopsych.2025.01.026. Epub 2025 Feb 6. Biol Psychiatry. 2025. PMID: 39922446
-
Neuropsychiatric symptoms in the prodromal stages of dementia.Curr Opin Psychiatry. 2014 May;27(3):230-5. doi: 10.1097/YCO.0000000000000050. Curr Opin Psychiatry. 2014. PMID: 24613979 Review.
-
Does the neuropsychiatric inventory predict progression from mild cognitive impairment to dementia? A systematic review and meta-analysis.Ageing Res Rev. 2020 Mar;58:101004. doi: 10.1016/j.arr.2019.101004. Epub 2019 Dec 24. Ageing Res Rev. 2020. PMID: 31881368
Cited by
-
Mild behavioral impairment linked to progression to Alzheimer's disease and cortical thinning in amnestic mild cognitive impairment.Front Aging Neurosci. 2023 Jan 4;14:1051621. doi: 10.3389/fnagi.2022.1051621. eCollection 2022. Front Aging Neurosci. 2023. PMID: 36688162 Free PMC article.
-
Correlates of Conversion from Mild Cognitive Impairment to Dementia with Lewy Bodies: Data from the National Alzheimer's Coordinating Center.J Alzheimers Dis. 2022;86(4):1643-1654. doi: 10.3233/JAD-215428. J Alzheimers Dis. 2022. PMID: 35213374 Free PMC article.
-
Mild Behavioral Impairment in Psychogeriatric Patients: Clinical Features and Psychopathology Severity.J Clin Med. 2023 Aug 21;12(16):5423. doi: 10.3390/jcm12165423. J Clin Med. 2023. PMID: 37629464 Free PMC article.
-
Neuropsychiatric Inventory in Community-Dwelling Older Adults with Mild Cognitive Impairment and Dementia.J Alzheimers Dis. 2019;68(2):669-678. doi: 10.3233/JAD-180641. J Alzheimers Dis. 2019. PMID: 30856109 Free PMC article.
-
Affective Neuropsychiatric Symptoms as Early Signs of Dementia Risk in Older Adults.J Alzheimers Dis. 2020;77(3):1195-1207. doi: 10.3233/JAD-200190. J Alzheimers Dis. 2020. PMID: 32925031 Free PMC article.
References
-
- Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288:1475–1483. - PubMed
-
- Steinberg M, Tschanz JT, Corcoran C, Steffens DC, Norton MC, Lyketsos CG, Breitner JC. The persistence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2004;19:19–26. - PubMed
-
- Palmer K, Lupo F, Perri R, Salamone G, Fadda L, Caltagirone C, Musicco M, Cravello L. Predicting disease progression in Alzheimer’s disease: the role of neuropsychiatric syndromes on functional and cognitive decline. J Alzheimers Dis. 2011;24:35–45. - PubMed
Publication types
MeSH terms
Grants and funding
- P30 AG013854/AG/NIA NIH HHS/United States
- P30AG028383/AG/NIA NIH HHS/United States
- P50AG005133/AG/NIA NIH HHS/United States
- AG035982/AG/NIA NIH HHS/United States
- P30 AG010124/AG/NIA NIH HHS/United States
- P50 AG023501/AG/NIA NIH HHS/United States
- P50 AG005142/AG/NIA NIH HHS/United States
- MH086881/MH/NIMH NIH HHS/United States
- P50 AG005131/AG/NIA NIH HHS/United States
- P30 AG010133/AG/NIA NIH HHS/United States
- T32 AG027668/AG/NIA NIH HHS/United States
- P50 AG016574/AG/NIA NIH HHS/United States
- P50 AG005146/AG/NIA NIH HHS/United States
- P30 AG035982/AG/NIA NIH HHS/United States
- P50 AG008702/AG/NIA NIH HHS/United States
- U01 AG016976/AG/NIA NIH HHS/United States
- P30 AG008051/AG/NIA NIH HHS/United States
- P50 AG005681/AG/NIA NIH HHS/United States
- P30 AG013846/AG/NIA NIH HHS/United States
- P30AG010124/AG/NIA NIH HHS/United States
- P50 AG005136/AG/NIA NIH HHS/United States
- P30 AG012300/AG/NIA NIH HHS/United States
- R01 AG038893/AG/NIA NIH HHS/United States
- P50 AG016573/AG/NIA NIH HHS/United States
- P50 AG016570/AG/NIA NIH HHS/United States
- P50 AG005134/AG/NIA NIH HHS/United States
- P30 AG008017/AG/NIA NIH HHS/United States
- P30 AG010161/AG/NIA NIH HHS/United States
- P50 AG025688/AG/NIA NIH HHS/United States
- T32AG027668/AG/NIA NIH HHS/United States
- P50 AG005133/AG/NIA NIH HHS/United States
- P50AG005136/AG/NIA NIH HHS/United States
- P50 AG005138/AG/NIA NIH HHS/United States
- AG038893/AG/NIA NIH HHS/United States
- P30 AG010129/AG/NIA NIH HHS/United States
- P30 AG019610/AG/NIA NIH HHS/United States
- R01 MH086881/MH/NIMH NIH HHS/United States
- P30 AG028383/AG/NIA NIH HHS/United States
- P50 AG033514/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical